Whalesbook
Financial Performance Deteriorates, Leading to Rating Downgrade
Dishman Carbogen Amcis Limited (DCAL) is facing significant financial headwinds, prompting India Ratings & Research (Ind-Ra) to downgrade its debt instruments. The rating agency has assigned an 'IND A' rating with a 'Negative' outlook to the company's non-convertible debentures (NCDs) and bank facilities. This downgrade reflects persistent concerns over DCAL's high net adjusted leverage, which has remained elevated, and a contraction in its EBITDA margins. These margins have fallen below the levels seen before the company's EDQM (European Directorate for the Quality of Medicines & HealthCare) related issues, indicating challenges in operational efficiency and business scaling.
On a consolidated basis, the EBITDA margin for the third quarter of FY26 (October-December 2025) stood at a concerning 15.7%, a sharp drop from 22.8% recorded in the same period last year (3QFY25). While the nine-month period of FY26 (April-December 2025) shows a slightly improved EBITDA margin of 19.35% compared to FY25 (17.3%) and FY24 (11%), it still lags behind the healthier 24.46% seen in FY20, prior to the EDQM issues. Consolidated revenue for the nine months grew a modest 4.3% year-on-year to INR 20,805 million. However, consolidated EBITDA (net of leases) for the first half of FY26 was INR 2,545 million, significantly lower than INR 4,189 million in FY25.
The standalone performance paints an even starker picture. While standalone revenue for 9MFY26 surged by 45% to INR 1,628.4 million, the EBITDA for the same period plummeted to INR 38.4 million from INR 718 million in FY25. This resulted in a drastic fall in the standalone EBITDA margin to just 2.4% from 17.95% in FY25.
High Leverage and Working Capital Strain Persist
DCAL's balance sheet remains under pressure due to high debt levels. Consolidated net adjusted leverage improved to 3.20x in 1HFY26 from 3.92x in FY25, but Ind-Ra expects it to stay above 3x in FY26. The standalone leverage is even more concerning, standing at a high 9.94x in FY25. Total debt, excluding lease liabilities, stood at INR 22,443 million in 1HFY26.
Interest coverage, a crucial metric for debt servicing ability, is also weak. Consolidated gross adjusted interest coverage improved to 2.74x in FY25, but the standalone coverage was critically low at 0.96x in FY25, indicating potential difficulty in meeting interest obligations from standalone operations. The finance cost for bank borrowings alone was INR 1,526 million in FY25.
Working capital management is another area of concern. The net working capital as a percentage of sales remained high at 35% in FY25, and the working capital cycle stretched to 180 days from 157 days in FY24, primarily due to an increase in the receivable period to 90 days. Furthermore, standalone net cash flow from operations turned negative in 1HFY26, highlighting cash generation challenges.
Management's Strategy and Capital Raise Plans
To address these issues, DCAL's management plans to raise capital of up to INR 10 billion through a Qualified Institutional Placement (QIP) or preferential shares. The primary goal is to repay high-cost debt and bring down the net adjusted leverage to below 2.5x. The company aims to raise approximately INR 7 billion in the first half of FY27, subject to market conditions.
Management guidance suggests an improvement in EBITDA margins to 19%-20% for FY26 and further in FY27, supported by expected ramp-ups at its Bavla (India) and French facilities. They also anticipate a higher contribution from commercial revenue over development revenue in the latter half of FY26. Annual maintenance capital expenditure (CapEx) is projected to be between CHF 20 million and CHF 25 million for the next three years, expected to be funded by internal accruals.
Peer Comparison
In the competitive CRAMS (Contract Research and Manufacturing Services) sector, companies like Divi's Laboratories and Laurus Labs have generally demonstrated more robust margin profiles and leverage ratios in recent years. While Syngene International also faces project-based revenue fluctuations, its financial metrics have often been perceived as more stable than DCAL's current standing. Aarti Industries, another player with diversified chemical manufacturing, has also navigated market cycles with generally lower leverage. The current downgrade for DCAL highlights its underperformance relative to some peers who have managed their expansion and debt more effectively, potentially impacting its ability to secure new contracts or attract partnerships amid stiff competition.
Investor Risks & Governance
Consistently High Leverage: Consolidated net adjusted leverage is expected to remain above 3x in FY26, with standalone leverage at a critical 9.94x in FY25. This high debt burden limits financial flexibility and increases interest costs.
Margin Compression: EBITDA margins are lower than historical pre-EDQM levels, impacted by slower business ramp-ups and initial costs for new facilities, leading to lower asset utilization and profitability.
Stretched Working Capital: The increase in the working capital cycle to 180 days in FY25, driven by higher receivables, ties up significant cash and could strain liquidity.
Standalone Operations Weakness: Negative standalone operating cash flow and very low interest coverage highlight the financial vulnerability of its domestic operations.
Forex Exposure: Adverse foreign exchange fluctuations could further impact leverage calculations as a substantial portion of revenue and debt is in foreign currencies.
There is no mention of past fraud, SEBI penalties, or specific governance issues beyond the financial performance and leverage concerns highlighted by Ind-Ra. The capital raise plan signals a proactive step by management to deleverage the balance sheet.